Egon Pfarr

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

David Fitchett, Silvio E. Inzucchi, Christopher P. Cannon et al. · Circulation · 2019 · 358 citations · Full text

Medicine, Cardiology, Pharmacology +17

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function

Faı̈ez Zannad, João Pedro Ferreira, Stuart Pocock et al. · Circulation · 2020 · 278 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin

David Z.I. Cherney, Mark E. Cooper, Ilkka Tikkanen et al. · Kidney International · 2017 · 245 citations · Full text

Medicine, Nephrology, Pharmacology +11

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Subodh Verma, C. David Mazer, David Fitchett et al. · Diabetologia · 2018 · 125 citations · Full text

Medicine, Cardiology, Surgery +17

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Preserved Trial

Abhinav Sharma, João Pedro Ferreira, Faı̈ez Zannad et al. · European Journal of Heart Failure · 2023 · 65 citations · Full text

Medicine, Cardiology, Pharmacology +17